SCHEMBL2789188

SCHEMBL2789188

NC(=O)C1CCCCC1c1c2ccc(=O)c(O)c-2oc2c(O)c(O)ccc12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 10/20 0.82
GNB1 P62873 10/20 0.82
HPGD P15428 4/20 0.82
ALOX15 P16050 4/20 0.82
HSD17B10 Q99714 4/20 0.82
HSPA1A P0DMV8 4/20 0.82
HSPA8 P11142 4/20 0.82
CYP2C9 P11712 3/20 0.82
CYP2C19 P33261 3/20 0.82
CYP1A2 P05177 2/20 0.82
HIF1A Q16665 2/20 0.82
TSHR P16473 1/20 0.82
GRK2 P25098 1/20 0.82
PHLPP2 Q6ZVD8 1/20 0.82
BRCA1 P38398 3/20 0.50
CDC25A P30304 2/20 0.49
CDC25B P30305 2/20 0.49
ALDH1A1 P00352 1/20 0.49
STAT6 P42226 1/20 0.49
GAPDH P04406 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2778459 0.90 GNG2 (1.00) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891725 0.90 GNG2 (1.00) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL16556406 0.90 GNG2 (1.00) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891733 0.85 GNG2 (0.72) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891706 0.84 GNG2 (0.74) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891722 0.82 GNG2 (0.71) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891724 0.82 GNG2 (0.71) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891728 0.82 GNG2 (0.71) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13891751 0.81 GNG2 (0.69) GNG2GNB1HPGDALOX15HSD17B10
SCHEMBL13352371 0.80 GNG2 (0.68) GNG2GNB1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-8975259-B2 Compositions and methods for inhibiting G protein signaling UNIVERSITY OF ROCHESTER (US) 2015-03-10 US disclosed
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2010-05-27 US disclosed
EP-2147310-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING University of Rochester (US) 2010-01-27 EP disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A9 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIV ROCHESTER (US) 2009-04-16 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed
WO-2009020677-A2 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING UNIVERSITY OF ROCHESTER (US) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130505-A1 COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING GNAI1, GNAI3, GNAI2 GNG2 5/4885GNB1 4/4885HPGD 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.